<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34036533</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-2019</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric drugs</Title>
          <ISOAbbreviation>Paediatr Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viloxazine: Pediatric First Approval.</ArticleTitle>
        <Pagination>
          <StartPage>403</StartPage>
          <EndPage>409</EndPage>
          <MedlinePgn>403-409</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40272-021-00453-3</ELocationID>
        <Abstract>
          <AbstractText>Viloxazine (QELBREE<sup>™</sup>), a selective norepinephrine reuptake inhibitor, is being developed by Supernus Pharmaceuticals as a non-stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. This is a novel formulation of a pharmacological agent formerly marketed in Europe for the treatment of depression in adults. Viloxazine received its first pediatric approval in April 2021 in the USA for the treatment of ADHD in pediatric patients aged 6-17 years. Approval was based on positive results from a series of short-term phase III clinical trials in which viloxazine improved the severity of ADHD symptoms in children and adolescents with diagnosed ADHD. Viloxazine is available as extended-release capsules for once-daily oral administration. This article summarizes the milestones in the development of viloxazine leading to this first pediatric approval for ADHD.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lamb</LastName>
            <ForeName>Yvette N</ForeName>
            <Initials>YN</Initials>
            <AffiliationInfo>
              <Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Paediatr Drugs</MedlineTA>
        <NlmUniqueID>100883685</NlmUniqueID>
        <ISSNLinking>1174-5878</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
          <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>7</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34036533</ArticleId>
        <ArticleId IdType="doi">10.1007/s40272-021-00453-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s40272-021-00453-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Supernus Pharmaceuticals. Supernus announces issuance of first use patents protecting SPN-812 as a novel non-stimulant ADHD product [media release]. 2014. http://www.supernus.com .</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pozzi M, Bertella S, Gatti E, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs. 2020;25(4):395–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14728214.2020.1820481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutler AJ, Mattingly GW, Jain R, et al. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2020;2020:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852920001984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. QELBREE™ (viloxazine extended-release capsules), for oral use: US prescribing information. 2021. http://www.accessdata.fda.gov/ . Accessed 7 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Supernus announces FDA approval of Qelbree<sup>TM</sup> (SPN-812) for the treatment of ADHD [media release]. 2021. http://www.supernus.com .</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals. SPN-812 ADHD adult study topline results. 2020. http://ir.supernus.com/ .</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Form 10-K (annual report): filed 03/21/14 for the period ending 12/31/13. 2014. http://ir.supernus.com/ . Accessed 7 May 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Vieira ML, Huang AB, Bhatt PP. United State patent: patent no. US 9,603,853 B2. 2017. http://patents.google.com/ . Accessed 7 May 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00498254.2020.1767319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2021.01.027 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2021.01.027</ArticleId>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, et al. Extended-release viloxazine (SPN-812) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents: topline results of a phase 3, randomized, double-blind, placebo-controlled study (P302) [abstract and poster]. Neurotherapeutics. 2019;16(3):914–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, et al. A phase 3, randomized, double-blind, placebo-controlled study (P302): efficacy and safety of extended-release viloxazine in adolescents with ADHD [abstract no. 112]. CNS Spectr. 2020;25(2):272–3.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34036533</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-2019</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Paediatric drugs</Title>
          <ISOAbbreviation>Paediatr Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viloxazine: Pediatric First Approval.</ArticleTitle>
        <Pagination>
          <StartPage>403</StartPage>
          <EndPage>409</EndPage>
          <MedlinePgn>403-409</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40272-021-00453-3</ELocationID>
        <Abstract>
          <AbstractText>Viloxazine (QELBREE<sup>™</sup>), a selective norepinephrine reuptake inhibitor, is being developed by Supernus Pharmaceuticals as a non-stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. This is a novel formulation of a pharmacological agent formerly marketed in Europe for the treatment of depression in adults. Viloxazine received its first pediatric approval in April 2021 in the USA for the treatment of ADHD in pediatric patients aged 6-17 years. Approval was based on positive results from a series of short-term phase III clinical trials in which viloxazine improved the severity of ADHD symptoms in children and adolescents with diagnosed ADHD. Viloxazine is available as extended-release capsules for once-daily oral administration. This article summarizes the milestones in the development of viloxazine leading to this first pediatric approval for ADHD.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lamb</LastName>
            <ForeName>Yvette N</ForeName>
            <Initials>YN</Initials>
            <AffiliationInfo>
              <Affiliation>Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Paediatr Drugs</MedlineTA>
        <NlmUniqueID>100883685</NlmUniqueID>
        <ISSNLinking>1174-5878</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
          <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>7</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34036533</ArticleId>
        <ArticleId IdType="doi">10.1007/s40272-021-00453-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s40272-021-00453-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Supernus Pharmaceuticals. Supernus announces issuance of first use patents protecting SPN-812 as a novel non-stimulant ADHD product [media release]. 2014. http://www.supernus.com .</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JEP.S256586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000001361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pozzi M, Bertella S, Gatti E, et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs. 2020;25(4):395–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14728214.2020.1820481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutler AJ, Mattingly GW, Jain R, et al. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2020;2020:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852920001984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. QELBREE™ (viloxazine extended-release capsules), for oral use: US prescribing information. 2021. http://www.accessdata.fda.gov/ . Accessed 7 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Supernus announces FDA approval of Qelbree<sup>TM</sup> (SPN-812) for the treatment of ADHD [media release]. 2021. http://www.supernus.com .</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals. SPN-812 ADHD adult study topline results. 2020. http://ir.supernus.com/ .</Citation>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Form 10-K (annual report): filed 03/21/14 for the period ending 12/31/13. 2014. http://ir.supernus.com/ . Accessed 7 May 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Vieira ML, Huang AB, Bhatt PP. United State patent: patent no. US 9,603,853 B2. 2017. http://patents.google.com/ . Accessed 7 May 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00498254.2020.1767319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2020.05.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2021.01.027 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2021.01.027</ArticleId>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, et al. Extended-release viloxazine (SPN-812) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents: topline results of a phase 3, randomized, double-blind, placebo-controlled study (P302) [abstract and poster]. Neurotherapeutics. 2019;16(3):914–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Chowdhry FA, et al. A phase 3, randomized, double-blind, placebo-controlled study (P302): efficacy and safety of extended-release viloxazine in adolescents with ADHD [abstract no. 112]. CNS Spectr. 2020;25(2):272–3.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1087054719836159</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
